Your browser doesn't support javascript.
loading
No evidence of disease versus residual disease in long-term responders to first-line HER2-targeted therapy for metastatic breast cancer.
Veitch, Zachary; Ribnikar, Domen; Tilley, Derek; Tang, Patricia A; King, Karen; Bedard, Philippe L; Lupichuk, Sasha; Cescon, David W.
Afiliación
  • Veitch Z; Department of Medical Oncology and Hematology, St Michael's Hospital, Toronto, ON, Canada. veitchz@rvh.on.ca.
  • Ribnikar D; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada. veitchz@rvh.on.ca.
  • Tilley D; Medical Oncology Department, Institute of Oncology Ljubljana, Ljubljana, Slovenia.
  • Tang PA; Cancer Care Alberta, Alberta Health Services, Calgary, AB, Canada.
  • King K; Department of Medical Oncology, Tom Baker Cancer Centre, Calgary, AB, Canada.
  • Bedard PL; Department of Medical Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada.
  • Lupichuk S; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.
  • Cescon DW; Department of Medical Oncology, Tom Baker Cancer Centre, Calgary, AB, Canada.
Br J Cancer ; 126(6): 881-888, 2022 04.
Article en En | MEDLINE | ID: mdl-34931041
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias de la Mama Tipo de estudio: Observational_studies / Prognostic_studies Límite: Female / Humans Idioma: En Revista: Br J Cancer Año: 2022 Tipo del documento: Article País de afiliación: Canadá
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias de la Mama Tipo de estudio: Observational_studies / Prognostic_studies Límite: Female / Humans Idioma: En Revista: Br J Cancer Año: 2022 Tipo del documento: Article País de afiliación: Canadá